Minimal Residual Disease in Paediatric ALL: Significance and Methodological Approaches

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F24%3A10494883" target="_blank" >RIV/00064203:_____/24:10494883 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/24:10494883

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-71180-0_6" target="_blank" >https://doi.org/10.1007/978-3-031-71180-0_6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-71180-0_6" target="_blank" >10.1007/978-3-031-71180-0_6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Minimal Residual Disease in Paediatric ALL: Significance and Methodological Approaches

Popis výsledku v původním jazyce

Minimal residual disease has played a key role in the treatment of childhood acute lymphoblastic leukaemia for more than two decades. It has been applied in all stages of treatment, including modern immunotherapies. Classical methods for detection and quantification of minimal residual disease have undergone a challenging process of standardization, allowing for risk stratification and prognostication in large international treatment trials. At the same time, new technological approaches are emerging that promise higher specificity and potentially higher sensitivity of detection. The use of new approaches to monitor minimal residual disease also provides new insights into the biology of some subtypes of childhood acute lymphoblastic leukaemias.

Název v anglickém jazyce

Minimal Residual Disease in Paediatric ALL: Significance and Methodological Approaches

Popis výsledku anglicky

Minimal residual disease has played a key role in the treatment of childhood acute lymphoblastic leukaemia for more than two decades. It has been applied in all stages of treatment, including modern immunotherapies. Classical methods for detection and quantification of minimal residual disease have undergone a challenging process of standardization, allowing for risk stratification and prognostication in large international treatment trials. At the same time, new technological approaches are emerging that promise higher specificity and potentially higher sensitivity of detection. The use of new approaches to monitor minimal residual disease also provides new insights into the biology of some subtypes of childhood acute lymphoblastic leukaemias.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Acute Lymphoblastic Leukemia in Children and Adolescents

ISBN

978-3-031-71179-4

Počet stran výsledku

11

Strana od-do

95-105

Počet stran knihy

397

Název nakladatele

Springer

Místo vydání

Cham

Kód UT WoS kapitoly

—